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A B S T R A C T
Cancer is a leading cause of mortality and morbidity worldwide. Around 90% of deaths are caused by metastasis
and just 10% by primary tumor. The advancement of treatment approaches is not at the same rhythm of the
disease; making cancer a focal target of biomedical research. To enhance the understanding and prompts the
therapeutic delivery; concepts of tissue engineering are applied in the development of in vitro models that can
bridge between 2D cell culture and animal models, mimicking tissue microenvironment. Tumor spheroid re-
presents highly suitable 3D organoid-like framework elucidating the intra and inter cellular signaling of cancer,
like that formed in physiological niche. However, spheroids are of limited value in studying critical biological
phenomenon such as tumor-stroma interactions involving extra cellular matrix or immune system. Therefore, a
compelling need of tailoring spheroid technologies with physiologically relevant biomaterials or in silico models,
is ever emerging. The diagnostic and prognostic role of spheroids rearrangements within biomaterials or mi-
croﬂuidic channel is indicative of patient management; particularly for the decision of targeted therapy.
Fragmented information on available in vitro spheroid models and lack of critical analysis on transformation
aspects of these strategies; pushes the urge to comprehensively overview the recent technological advancements
(e.g. bioprinting, micro-ﬂuidic technologies or use of biomaterials to attain the third dimension) in the shed of
translationable cancer research. In present article, relationships between current models and their possible ex-
ploitation in clinical success is explored with the highlight of existing challenges in deﬁning therapeutic targets
and screening of drug eﬃcacy.
1. Biological fundaments of metastasis progression
The alterations in oncogenes and tumor suppressors underlie the
autonomous defects in cells; the characteristics of cancer initiation
within a healthy non-transformed cellular microenvironment. But tu-
mors are not simply autonomous neoplastic cells; instead the cross-talk
among tumorous or malignant and non-malignant cells, signals and
secretory proteins (such as cytokines) inﬂuences cancer development,
metastasis formation and dissemination (Barcellos-Hoﬀ, Lyden, &
Wang, 2013; Bremnes et al., 2011). Metastasis is “the spread of cancer
cells from primary tumor to secondary locations within the body”
(Barcellos-Hoﬀ et al., 2013). The cascade events of metastasis start with
the growth of primary tumor cells, which needs the supply of blood to
support their metabolism — the phenomenon known as angiogenesis.
The proliferating tumor cells commandees available vasculature or
stimulate neovessel generation for continuous supply of oxygen, nu-
trients and growth factors. The rapid proliferation soon exhausts the
supply of nutrient and oxygen; becomes hypoxic (Thoma,
Zimmermann, Agarkova, Kelm, & Krek, 2014). The newly formed blood
vessel oﬀers the escape route to tumor cells, that then enter into cir-
culatory system (such as blood or lymphatic system) — the process
known as intravation. Migratory tumor cells surviving within the cir-
culation, extravasate into a near or far guest-tissue/organ and start
formation of a secondary tumor mass as depicted in Fig. 1. Despite of
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available information in hand is not enough for addressing major
questions, namely: how cancer cells learn to become metastatic? Why
tumor cell colonizes at speciﬁc sites? Which is “the signal” for new
tissue/organ selection? Recently, exosomes are recognized as crucial
factor in regulating organ-speciﬁc metastasis selection (Hoshino et al.,
2015; Kuzet & Gaggioli, 2016).
Following the arrival at secondary site, circulating cancer cells may
turn into solitary cells or initiate small pre-angiogenic metastases or
larger vascularized metastases (Chambers, Groom, & MacDonald,
2002). In each case, a small subset of cells executes the pre-deﬁned
action, major portion either undergoes dormancy or die. The dormant
solitary cells refer as dormat tumor cells (DTCs) that neither proliferate
nor died; remaining as silent (Cuperlovic-Culf, Culf, Touaibia, & Lefort,
2012; Hensel, Flaig, & Theodorescu, 2013). DTCs are identiﬁed as po-
tential target in premature metastasis detection, concretely in me-
senchymal transition (Hensel et al., 2013) and extensively explored as a
prognostic marker in various solid cancers or complementary strategy
for metastasis monitoring (Giuliano et al., 2014; Lohr et al., 2014).
However, solitary cells and micrometastases are clinically undetectable;
only vascularized metastases are clinically detectable. Up till now cel-
lular markers such as Ki-67 (to detect proliferation), terminal deox-
ynucleotidyl transferase dUTP labelling (TUNEL) assay and expression
of M30 (to detect apoptosis) (Hensel et al., 2013; Newbold, Martin,
Cullinane, & Bots, 2014) are available to identify DTCs.
Cancer stroma contains few ﬁbroblasts, mesenchymal cell types
distinctive to each tissue type embedded within the proteinaceous
network of extracellular matrix (more distinguishably collagen, elastin,
ﬁbrin and ﬁbronectin) (Amann et al., 2014; Kimlin, Casagrande, &
Virador, 2013; Nyga, Cheema, & Loizidou, 2011). At the intravation
front stromal changes take place, such as appearance of carcinoma-as-
sociated ﬁbroblasts (CAFs); which is transdiﬀerentiated from the
normal ﬁbroblasts in presence of cancer-driven cytokine, Transforming
Growth Factor-β (TGF-β) (Azarin et al., 2015; Bremnes et al., 2011;
Kuchnio et al., 2015; Ursini-Siegel & Siegel, 2016). CAFs are responsible
for tumor cells invasion and regulation of tumorigenesis by inducing
diﬀerentiation of endothelial cells into capillary-like microvasculature
using cell surface receptor integrins (Cuperlovic-Culf et al., 2012; Joyce
& Pollard, 2009). Immune and inﬂammatory cell activates the pro-
duction of chemokines, cytokines and exosomes that involve in re-
modeling of local tissue; contributing to resistance to traditional che-
motherapy (Bremnes et al., 2011).
Other relevant mechanisms associated with the success of tumor
development includes involvement of nerves in dissemination of tumor
(Amit, Na'ara, & Gil, 2016). Stellate cells (star shaped cells radiating
from cell body during dendritic processes) activates on exposure to pre-
malignant cells, malignant cells, hypoxia and inﬂammation (Vonlaufen
et al., 2008). TGF-β expressed by cancer cells stimulates stellate cells,
results in enhanced expression of matrix metalloproteinases causing the
degradation of peri-neural extracellular matrix (ECM) and migration of
cancer cells through tissue (Pantel & Brakenhoﬀ, 2004). The injured
nerve regenerates nerve growth factor and neurturin that recruit mac-
rophages; which further releases glial cell derived neurotrophic factor
in support to neural tracking and cancer cell invasion (Amit et al.,
2016). The cross-talk between neuron–tumor enhances cancer cell ad-
hesion and further secretion of neurotrophin 3, which triggers Schwann
cells involvement. Schwann cells draw cancer cells into peri-neural
niche and recruit them to degrade peri-neural ECM facilitating the
survival, migration and cancer invasiveness.
Regardless of current understanding, the incompetence to treat
metastasis results cancer-related deaths; challenging modern oncolo-
gists up till now. Because of these uncertainties, it is necessary to de-
velop more realistic pre-clinical models that allow to gain the under-
lying insight on the molecular mechanisms driving metastasis
formation and progression (Alemany-Ribes & Semino, 2014; Colacino,
Fig. 1. Formation of metastasis from colorectal primary tumor to secondary bone tumor. (A) begin tumor microenvironment formation in colon primary tumor; (B) malignant micro-
environment development with carcinoma-associated ﬁbroblasts recruitment and apoptotic nucleon; (C) microenvironment maturation with vasculogenesis formation; (D) tumor cells
invading circulatory system by extravasation towards a new tissue/organ; (E) new host colonization forming a secondary tumor in bone.
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2016). The state-of-art of cancer research presently involves in in-
vestigating the signature of cancer cells on its microenvironment or
vice-versa employing the principles of tissue engineering and the
structure-function relationship of engineered construct to reveal che-
motherapeutics eﬀects that are critically summarized in several recent
reviews (Eglen & Klein, 2017; Fang & Eglen, 2017). The present review
integrates the literatures published on spheroid culture along with
mathematical models, since we last review the ﬁeld (Carvalho, Lima,
Reis, Correlo, & Oliveira, 2015) to update the possibility of exploiting
them as predictive tools for creating complex 3D disease environment
or drug discovery.
2. Pre-clinical models for metastasis
The percentage of transition of cancer therapeutics into clinical
success is remarkably low due to sub-optimal pre-clinical validation,
inherently complicated nature of disease and limited pre-clinical assay
tools (Begley & Ellis, 2012). The complete expense and complexity of
cancer microenvironmental cues experienced by cancer cells during
metastatic cascade needs to be studied using appropriate metastatic
models for the improvement of therapeutic outcome. Both non-animal
and animal models are exploited in preclinical studies (Colacino, 2016;
Dranoﬀ, 2011; van Marion, Domanska, Timmer-Bosscha, &
Walenkamp, 2016).
The basic 3D organotypic culture system in cancer modeling has
adapted ~40 years ago; considerably contributing to the insight of
cellular response towards chemotherapy (Hickman et al., 2014), hy-
perthermia (Dubessy, Merlin, Marchal, & Guillemin, 2000) and radio-
therapy-photodynamic treatment (Desoize & Jardillier, 2000). The
success of cancer spheroids as high-throughput analysis system is
regulated on choice of appropriate model as per the therapeutic re-
quirement (Costa et al., 2016). Mono-culture of tumor cells into
spheroid serves as prevailing tool to investigate the regulators of tumor
micro-environment or responsiveness of therapeutics associated with
metabolic and proliferative gradients such as altered sensitivity of hy-
poxic tumor cells or chemotherapeutic resistance (Shield, Ackland,
Ahmed, & Rice, 2009). It also greatly contribute to pronounce eﬀect of
radio-sensitization in 3D organotypic setting; particularly transient
delay in G2 phase, induction of apoptosis and onset of DNA strand
break. However, mono cell type spheroid culture system lacks hetero-
genous cancerous stromal compartment. Investigators address this issue
by co-culturing cancer cells with ﬁbroblasts (Gottfried, Kunz-Schughart,
Andreesen, & Kreutz, 2006), immune cells (Orre & Rogers, 1999) or
stem cells (Wang et al., 2010). Nevertheless, the study of systemic cell
spread or preferential homing to speciﬁc organ needs the involvement
of living system, therefore, inclusion of in vivo models is needed.
Models such as fruit ﬂy (Drosophila melanogaster), zebraﬁsh (Danio
rerio) provide the in vivo microenvironment to cancer cells to grow
(Alemany-Ribes & Semino, 2014; van Marion et al., 2016). However,
lack of various non-conserved sequences limits the recapitulation of
genetic complexity of human tumors in zebraﬁsh (Danio rerio)
(Alemany-Ribes & Semino, 2014; van Marion et al., 2016). Chor-
ioallantoic membrane (CAM) of fertilized chicken eggs serves suitable
in investigating angiogenesis, extravation and colonization but limits
with short assay span of 18 days (Alemany-Ribes & Semino, 2014; van
Marion et al., 2016).
For large scale study of complex metastatic process laboratory ani-
mals are included. The most common used animal model for deci-
phering malignant cancer still remains the mouse (Daphu et al., 2013;
Li, 2015). Preclinical primary or secondary metastatic xenograft models
using mouse able to recapitulate critical aspects of tumor development;
but of limited value from the fact that human tumor cells are implanted
and metastasized into an incompatible murine tissue environment. The
xenograft models are also increasingly being criticized for their nega-
tive impression of inter-species barriers that question the clinical re-
levance of these studies (Lee et al., 2012; Siolas & Hannon, 2013).
Further, the use of immune-compromised host animals; particularly
non-obese severe diabetic immune-deﬁcient species (Dranoﬀ, 2011;
Hibberd, Cossigny, & Quan, 2013; Li, 2015). Immunosurveillance is a
regulatory phenomenon of tumor stroma; signiﬁcantly contributing to
tumor initiation, progression, metastasis and therapeutic responses. As
a result, tumor grows faster in immune compromised animals compared
to wild type immunocompetent one (Engel et al., 1996). In addition,
continuous use of cell lines procures diverged expression of genes
compared to parental gene expression (Alemany-Ribes & Semino, 2014;
van Marion et al., 2016). As a consequence, patient derived tumor xe-
nografts (PDTX) are in practice (Tentler et al., 2012; Williams,
Anderson, Santaguida, & Dylla, 2013). PDTXs are promising for de-
velopment of personalized anti-cancer therapies, biomarkers and drug
screening. Additional value is added to PDTX in case of rare cancers
where pre-clinical models are absent (Hidalgo et al., 2011). However,
considerable time and cost burden of PDTX tumor models along with
diversity in subtypes in cancer patients limits its extensive use
(Williams et al., 2013).
Full murine models associated with metastasis modeling are broadly
categorized into two groups; syngeneic (fully immunocompetent animal
model) and genetically modiﬁed (Alemany-Ribes & Semino, 2014; van
Marion et al., 2016). In syngeneic model, both host and graft are of
same species (Khanna & Hunter, 2005). Knock-in or Knock-out gene
mutations are used in dissemination of cancer; causing change in me-
tastatic potential of resultant cancer cells. In genetically modiﬁed
cancer animal models, tumor develops at its natural sites and metas-
tasize to distant organ in presence of immune system comparable to
that of human (Khanna & Hunter, 2005). The earliest observation by Dr.
Loessner (Loessner, Little, Pettet, & Hutmacher, 2013) reveals the
spheroids and tumor tissues obtained from xenografts are softer than
ovarian tissue. However, whether cancer cells mechanically pre-con-
ditioning their metastatic site or not is still elusive. The overview, ad-
vantage and limitations of the existing models are depicted in Table 1.
The constraint of existing models needs improvement for better
translation of patient-speciﬁc treatment. Development of sophisticated
animal models and/or patient-unique ex vivo systems like organoids in
association with suitable read-out system may facilitate the therapeutic
translation. One of the promising strategies is incorporation of bioma-
terials into 3D cancer culture system. According to literature, the
missing gap of spheres growing in liquid culture media, is ECM
(Hickman et al., 2014). ECM is not an inert compartment; instead an
interactive component critically regulating the diﬀerentiation and in-
vasion of cancer cells. Cell surface receptor β1-integrin mediates ad-
hesion to ECM, up-regulates tumorigenicity in hematological and epi-
thelial malignancies and imparts doxorubicin and melphalan resistance
to small cell lung cancer and multiple myeloma cells; termed as cell-
adhesion-mediated drug resistance (Correia & Bissell, 2012; Sethi et al.,
1999). Integrin αvβ3 protects breast cancer cells by activating MAPK
pathway (Menendez et al., 2005). In addition, chemo-insensitive cancer
cells cultured on speciﬁc ECM components reveal prolong cell cycle
arrest after radiation treatment; providing time to repair radiation in-
duced damage in DNA at cell-cycle check points (Bartek & Lukas,
2001). Therefore, pre-formed spheroids embedded into or top of 3D
matrix for cell invasion and metastasis study become apparent.
During the incorporation of spheroids into 3D ECM, certain essential
conceptual requirements must be taken into serious consideration for
successful establishment of spheroid based therapeutic screening model
like spheroid size and geometry; which are mandatory prior to eﬃcient
scaling up spheroid system into preliminary drug screening models. The
penetration of drug into spheroid is visualized by confocal screening or
optical imaging technique; still lacks intense validation to their oper-
ating condition and high-throughput analysis of spheroids. The state-of-
art of micro-fabrication techniques and conditions achieved to adopt
cancer spheroid culture is highlighted in the following sections.
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Table 1
Preclinical metastases models: in vitro and in vivo.
Models General
descriptions
Applications Advantages Disadvantages Reference(s)
In vitro model(s)
2D
Adapted from Biomatrix©
Culture of cells in
monolayer
Endpoints assays. • Simple and cheap.• Well preservation of viability
and functions of primary cells.
Elongated, substrate
dependent and loss of
epithelial cell polarity.
Interactions are limited.
Kimlin et al. (2013),
Silva-Correia et al.
(2013)
3D
Adapted from Biomatrix©
Culture of cells in
multilayers,
allowing cellular
aggregation
Formation of
MCTSs
Drug screening
• Allows interaction between cells
and cell-ECM, regulate the
proliferation and diﬀerentiation
in space and time.
• Allows the study of invasion and
migration of cell (detectable by
standard methods like
immunohistochemistry, for
example), identifying the role of
several proteins involved in
metastatic behavior.
Formation of apoptotic and
necrotic nucleus
Li and Cui (2014),
van Marion et al.
(2016)
3D perfused culture
Adapted from Biohenuis© ref.
(Caicedo-Carvajal & Liu, 2012)
Dynamic system
that mimics the
blood circulation
by inducing
mechanical and
biological stimulus
Perfusion allows
controllable
homeostasis for
cancer growth
supporting long-
term drug testing
• Resemblance to human body
conditions, with control of
physiological conditions,
creating gradient of oxygen,
growth factors, some
biochemical signals and
interactions.
• Allows cell multilayers
formation, with low risk of
contamination.
Lack of suitable bio-assays and
imaging system suitable for
3D perfused culture.
Expensive; requires
specialized equipments
Caicedo-Carvajal
and Liu (2012),
Erapaneedi et al.
(2016); Li and Cui
(2014), Yan et al.
(2016)
Animal model(s)
Mouse
Adapted from ref. (Dranoﬀ, 2011)
Sub-divided in 2
broad groups:
- human
xenotrans-
plantation
model
- syngeneic
model
In vivo extravasion • Allow the development of
metastasis
• Incorporation of genetic
alterations.
Utilization of several
immunocompromised and/or
immune-deﬁcient host mice is
inadequate in modeling
immune human response.
Daphu et al. (2013),
Lee et al. (2012),
Newbold et al.
(2014), Santini
et al. (2012), Siolas
and Hannon (2013)
Fruit ﬂy Drosophila melanogaster
Adapted from ref. (Buchon,
Silverman, & Cherry, 2014)
Invertebrate
organism lacks
blood vessels
Study initial stages
of metastasis,
mainly the
mesenchymal
transition
• Genes and pathways for
tumorigenesis are largely
conserved between the ﬂy and
humans.
• Easy manipulation and cheap.
Fail to fully resemble
mammalian systems (lack of
homogeneous organs:
pancreas, liver and lungs.
Angiogenesis and the role of
immune system cannot be
studied. Thus, intravasion and
extravasion cannot be
modeled.
Feng and Martin
(2015), Murray
(2015), van Marion
et al. (2016)
Zebraﬁsh Danio rerio
Adapted from ref. (White, Rose, &
Zon, 2013)
Vertebrate model
due to aquatic life
mode
Observation and
analysis of micro-
environmental
interactions
• Allows live imaging of human
cancer cells and their
interaction with innate immune
system due the permeability to
small molecules and the
transparency of embryos
• obtained easily and in large
amount
• Can be easily manipulated• can be analyzed by simple
methods (as microscopy
observation)
The transplantation of cancer
cells to zebraﬁsh, or to
embryos does not able to
directly recapture cancer
initial stages (contrary to fruit
ﬂy).
Feng and Martin
(2015), Jeanray
et al. (2015), Simi,
Piotrowski, and
Nelson (2015)
Chorioallantoic membrane (CAM) of
fertilized chicken eggs
(Simple and with hydrogel)
Oﬀers a continuous
circulatory system.
Angiogenic tests • Able to extract information
about components involved in
metastasis progression, survival
factors in circulation and about
the transference to target
organs.
Unspeciﬁc inﬂammatory
reactions and impossibility to
study immune system. Limited
duration of assays (18 days).
Do not support the study of
complete metastasis cascade.
Bartlett et al.
(2014), Feng and
Martin (2015),
Manjunathan and
Ragunathan (2015),
Silva-Correia et al.
(2013), van Marion
et al. (2016)
T. Rodrigues et al. Pharmacology and Therapeutics xxx (xxxx) xxx–xxx
4
Table 2
Main characteristics of methods commonly used in culture of multicellular tumor spheroids.
Methods Applications Advantages Disadvantages References
Hanging drop (pipetting manual,
array plate)
• To study tumor physiology,
metabolism, cellular
organization and development
• Co-culture of cells and study
cellular cross-talk
• Drug screening
• Simple• Easy to scale-up and trace
MCTSs assembly
• Control of spheroid size by the
number of cells
• Formation of
homogeneous MCTSs
is diﬃcult, mainly in
size.
• Labor intensive and
present diﬃculties in
large-scale
production.
• Long-term of culture is
diﬃcult.
Alemany-Ribes and Semino
(2014), Hsiao et al. (2012),
Khanna, Bhatt, and
Dwarakanath (2013), Mehta
et al. (2012), Thoma et al.
(2014), Vinci et al. (2012)
Soft agar liquid overlay
Adapted from ref. (Hickman et al.,
2014)
• Study interactions between
tumor cells and ﬁbroblasts and
their role in tumor development
• Simple, ease in set-up • Formation of
homogeneous MCTSs
is diﬃcult
• Limitations in mass
transference and cell
viability
Alemany-Ribes and Semino
(2014), Hickman et al. (2014),
Khanna et al. (2013), Mehta
et al. (2012), Vinci et al.
(2012)
Rotative systems (spinner ﬂask, roller
bottle, gyratory shaker, NASA
bioreactor)
Adapted from
BioProcessInternational©
• Produce MCTSs in large scale• Allow co-culture of cells •
Provide constant and dynamic
culture conditions
• Eﬃcient for long-term cell
viability
• Low shear stress
• Formation of
homogeneous MCTSs
is diﬃcult
• Not useful for drug
screening
• Expensive
Alemany-Ribes and Semino
(2014), Khanna et al. (2013),
Vinci et al. (2012)
Microfabricated structures
(microchips and
microhydrophobic surfaces)
Adapted from ref. (Oliveira et al.,
2014)
• Perform 3D liver or stem cells
spheroids.
• Real-time imaging• Drug screening.
• Homogeneous and controlled
MCTSs, both in size and
number. The MCTS size is
deﬁned by pore size.
• Require specialized
equipment.
• Low screening yield.
Oliveira et al. (2014), Thoma
et al. (2014), van Marion et al.
(2016)
3D Scaﬀolds
Adapted from 3DBiotek ©.
• Produce bioartiﬁcial tissues,
most eﬀective for cancer drug/
therapeutics screening.
• Provides a 3D support,
allowing the MCTs study using
several techniques
• Expensive, requires
specialized equipment
for to build scaﬀold.
• Pooled screening
limited by low yield.
Alemany-Ribes and Semino
(2014), Khanna et al. (2013),
Lozano et al. (2015)
Assembly (magnetic, paramagnetic,
micro-robotic, liquid-based)
Adapted from Promega©.
• Incorporation of biomolecules
(proteins, nucleic acids,
carbohydrates, and lipids) to
form scalable functional
biomaterials for 3D cell culture
• Precision and reproducibility.
Allows the manipulation of
cells seeded in beads.
• Cells remodel their
microenvironment and secrete
their own ECM.
• Co-culture of diﬀerent cells.• Rapid cell aggregation.
• Require specialized
equipment and culture
conditions
Alemany-Ribes and Semino
(2014), Asghar et al. (2015),
Khanna et al. (2013), Zhu et al.
(2016)
Bioprinting • Develop complex 3Dstructure
via a layer-by-layer approach,
pattern living cells, biological
macromolecules, and
biomaterials.
• Form complex 3D geometries
from computer-aided designs.
• Allow designing geometry
aggregates; uniform number of
cells, size and composition
• Co-culture of diﬀerent cells, it
is able to simultaneously
deposit live cells, growth
factors along with biomaterial
• Eﬃcient, precise and rapid
• Diﬃcult control over
cell number and types
in individual droplets.
• Detected high stress
levels in cells.
• Require specialized
equipment, result
dependents of
operational technique.
Alemany-Ribes and Semino
(2014), Khanna et al. (2013),
Knowlton et al. (2015), Lee
et al. (2014), Yue et al. (2015)
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2.1. Multicellular tumor spheroids (MCTs): biology, in vitro developmental
strategies and statistical dissections for understanding cancer
Recently, multi-cellular tumor spheroid (MCTS) model is gaining
popularity because of its ability to strikingly mirror the three-dimen-
sional cellular context of in vivo cancer and the extended ﬂexibility to
adapt mono-co-culture system based on therapeutic requirements.
However, spheroid model is not a relevant tool for all malignant disease
cases and even in one cancer type, varies with patho-physiological
conditions (Friedrich, Ebner, & Kunz-Schughart, 2007). For instance,
non-solid cancers such as leukemia cells lack relevance of forming
spheroid; however, their drug resistance characteristic is the phenom-
enon of cell adherent phenotype. With reference to melanoma, skin
culture models are more appropriate to reﬂect tumorous behavior
(Friedrich et al., 2007). Spheroids well serve as preclinical models of
avascular metastases and solid tumors—provided the investigator is
well acquainted with the relevant limitations. Moreover, the spheroid
stroma resembles the intervascular micro-regions of sarcomas and
carcinomas including gliomas and glioblastomas; make them rational
choice by researchers. However, conduct trials of therapeutics of cen-
tral nervous system (CNS) metastasis in laboratory using spheroid is
diﬃcult due to lack of reasonable blood-brain barrier (BBB) model in
vitro (Bates, 2015). Size, low lipophilicity and sensitivity to multidrug
transporter by most present therapeutics, are the limiting factors to
cross BBB under physiological condition. Although, investigations like
local invasiveness of glioblastomas, its growth pattern can be carried
out using spheroids in association with appropriate ECM biomaterials
such as collagen (Stein, Demuth, Mobley, Berens, & Sander, 2007).
MCTSs are described as spherically symmetric aggregates of cells
analogous to tissues, with no artiﬁcial substrate for cell attachment. A
simple description of in vivo solid avascular tumor is included here for
the realization of general readers. In avascular spheroid, a number of
cells adhere to each other to form spherical cell mass; cells present at
the periphery are actively cycling while residing adjacent to capillaries
in situ (Kunz-Schughart, 1999). In contrast, the innermost region is
quiescent necrotic zone. The concentric heterogeneous cell gradient in
spheroid is representative of patho-physiological gradient and micro-
metastasis (break away of cancer cells from primary cancer sphere
through blood or lymph into other body parts for development of new
tumor) stage. When the critical size of cancer spheroid reaches beyond
500–600 μm, another secondary necrotic zone of 100–300 μm is de-
veloped surrounding the quiescent necrotic zone (Friedrich et al.,
2007). This is a viable rim of cells with limited oxygen, nutrients and
restricted inward-outward diﬀusion; while maintaining intracellular
homeostasis shortly till cell death. The sensitivity of tumor cells to-
wards patho-physiological stress situation within multi-cellular tumor
spheroid is dependent critically on their energy production under both
anaerobic and aerobic condition.
Oncogene driven altered uncontrolled proliferation lacks adequate
vascularization results in quick depletion of oxygen and nutrient in
tumor cell mass causing hypoxia (i.e. lack of oxygen) (Eales,
Hollinshead, & Tennant, 2016). Average oxygen diﬀusion limit is up to
100–200 μm in normal tissue; beyond this radius hypoxia occurs in
cancer sphere. Hypoxia acts as stimulus in cancer cells triggering vas-
cularization within tumor sphere by promoting angiogenesis with
chaotic architecture leading to non-laminar ﬂow of blood (Carmeliet &
Jain, 2000) at additional hypoxic regions. Within tumor spheroid, cells
those reside in close proximity of blood supply have immense access of
oxygen and nutrient and use aerobic oxidative phosphorylation sup-
porting rapid proliferation (rapidly proliferating outermost region)
(Martinez-Outschoorn, Peiris-Pages, Pestell, Sotgia, & Lisanti, 2017).
Cells far away from vasculature located at the center of spheroid are
anabolic cell population committing alternative metabolic pathways
like autophagy imparting adaptability to manage their energy need.
Such an alteration in metabolism pathways within cancer micro-
environment act as target for cancer treatment development. For more
in-depth understanding of cancer metabolic signaling pathways we
refer the readers to recent excellent reviews on cancer metabolism
(Martinez-Outschoorn et al., 2017) and hypoxia (Eales et al., 2016).
Though it perhaps impossible to state a common universal standard
protocol of spheroid culture and investigation applicable under all ex-
perimental circumstances. The common disposable methods for MCTSs
culture are: (i) hanging drop method (using conventional pipetting or
microarrays/special well-plates); (ii) rotary cell culture system; (iii)
culture into microﬂuidics chips; (iv) fabrication of the complex cell-
biomaterial by bio-printing; and (v) self-assembly (without any external
forces) (Erapaneedi, Belousov, Schafers, & Kiefer, 2016; Gu et al., 2015;
Hathaway et al., 2011). The main characteristics of each method are
summarized in Table 2 (Bartlett et al., 2014; Zhu, Holmes, Glazer, &
Zhang, 2016).
MCTSs fabrication platforms are expected to measure physiologi-
cally active substances to satisfy four main requirements (Gong et al.,
2015; Ota & Miki, 2011); including: (i) good controllability during the
formation of spheroids; (ii) allow culturing of formed spheroids for an
extended time (i.e., longer than one day) with real-time morphological
observations at any point; and (iii) incorporation of reagents such as
dye or chemical stimulus to cells. These strategies involve in special
non-adherent surface production. Non-adherent surfaces promote cell-
cell adhesions are most popular stationary phase for spheroid formation
or maintenance. The existence of large repertoire of such materials is
the proof of it and generally referred as microwell arrays. Polyethylene
glycol (PEG) surfaces impart the resistance against the adhesion of both
cells and proteins (Zhang, Desai, & Ferrari, 1998), while support the
bridging with micro-ﬂuidic advancement. Alternatively, poly-
dimethylsiloxane (PDMS) elastomers endure non-adhesive surface and
spheroid formation along with the degree of freedom for lithography
(Nakazawa, Izumi, & Mori, 2009). Micro-contact printing of collagen
adhesion motif on PEG-coated micro-wells acts as cell adhesion foci for
spheroid assembly (Fukuda, Sakai, & Nakazawa, 2006). The coating
surface is not uniformly relevant for all materials; round-bottom wells
treated with poly-hydroxyethyl methacrylate (0.5 wt%) in ethanol
(95%v/v) is advantageous (Ivascu & Kubbies, 2006), while ﬂat bottom
wells coated with agarose results semi-solid, concave, non-adherent
surface faciliating the formation of spheroids under the inﬂuence of
micro-gravity (Friedrich, Seidel, Ebner, & Kunz-Schughart, 2009).
Coating process can be tailored for the advancement of spheroid de-
velopment and to illustrate the hypoxia eﬀect on disease advancement
and vascularized models; with tremendous scope in fundamental and
applied spheroid based research (Eglen & Klein, 2017).
The resulting spheroids possess physiological cell-to-cell contacts,
secrete their own ECM and develop nutrient, drug and oxygen transfer
gradients similar to those found in physiological tissues. Moreover, the
MCTSs can be studied continuously in hanging drops, or transferred to
conventional cultured plates for further analysis or recovery (Hickman
et al., 2014; Qiu et al., 2015). All basic analytical tools such as mole-
cular analyses (DNA, RNA and protein) can be adapted well for 3D
spheroids and allow comparing with that of monolayer culture if the
analytical end point is a critical function of up or down regulation of a
gene or a set of genes. Several literatures depict the genomic stability of
multi-cellular spheroids, indicating the preservation of genomic proﬁle
of human malignant cells such as glioma in spheroid but lacks in
monolayer (De Witt Hamer, Leenstra, Van Noorden, & Zwinderman,
2009). Follow up strategies involve the employment of nanosilicon
(Premnath, Tan, & Venkatakrishnan, 2015), which is linked to nano-
particles or other nanostructures such as biosensors for cancer culture.
The critical application of this is in “matrisome” research, i.e. the
analysis of ECM and ECM-associated proteins for the development of
proteomics-based methods coupled with bioinformatics to analyze the
protein composition of ECM (Naba et al., 2012, 2014).
Statics are employed to further illustrate the mechanistic insight of
solid tumor growth and development. The spatio-temporal model for
avascular tumor growth narrates the size and shape change of tumor
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spheroid with experimental conditions and therapeutic exposure, which
is attractive to model mathematically. Brown and Palmer proposes a
probabilistic agent-based analysis technique based on time and size of
tumor for ovarian cancer to anticipate early detection of unsuspected
ovarian cancer and survival rate (Brown & Palmer, 2009). The model
postulates that ovarian tumors spend more than four years to develop
(stage I and stage II), reaches stage III and/or stage IV in approximately
one year before become clinically evident. The model then correlates
the developmental time with the size of tumor; to obtain 50% sensi-
tivity in tumor detection, the size of tumor needs to be< 1.3 cm. For
the reduction of serous ovarian cancer mortality rate by 50%, early
diagnostic screen needs to recognize tumor of< 0.5 cm. Despite the
diﬃculty in estimating the size of serous ovarian tumor with time; the
stimulation corborrate with clinical observations of advanced stage
ovarian tumor diameter, indicating “window of opportunity” of math-
ematical approach.
Shape or multidimensional proﬁling of spheroids are used to iden-
tify the molecular predictors of tumor phenotype by employing com-
puted morphometric approach (Han et al., 2010). The use of consensus
matrix and hierarchial clustering in predicting gene expression based
spheroid architecture able to identify the stability of sub-population
along with the shape and number of these sub-populations. This in silico
approach is useful in predicting anti-cancer therapeutic eﬃcacy in
diﬀerent sub-population of a typical cancer type.
The size of tumor spheroid changes upon growth, which is further
regulated by distribution of diﬀusion factors including oxygen, glucose
within the spheroid and is expressed with following equation (Byrne,
2010).
∫=
=
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dt R
F c r dr1 ( )
r
R
2
0
2
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Where function of (F) growth factor concentrations (C) such as
oxygen or glucose regulate net cell growth, which in turn inﬂuences the
spheroid size; R(t) the change in radius of the spheroid with time. The
distribution of growth factor within the spheroid is described as (Byrne,
2010):
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Where D is the diﬀusion co-eﬃcient of growth factor concentrations
(C) and g (c, R) represents the local rate of consumption; together
helpful to predict the physiological state of spheroid such as intra and
inter cellular interactions, survival state of cells in spheroid. For in-
stance, the threshold value of oxygen concentration in diﬀerent region
of spheroid delineates the physiological state of cells at that site; high
oxygen concentration is the zone of cell proliferation, intermediate
oxygen concentration is quiescence cell zone and very low oxygen
concentration is necrotic zone. Initially, an exponential growth phase is
encountered by spheroid antiquated by linear fugitive phase with
constant value of outer proliferating rim till the spheroid reach the
equilibrium size, where the death and growth of spheroid cells reached
balance. The agreement between experimental reports and mathema-
tical dynamic models contribute a realistic insight of disease progres-
sion and eﬀect of regulator distribution.
However, this simple model encounters limited applicability to the
consideration of a single cell population ignore stochastic eﬀects of
diﬀerent emerging clonal sub-population and involvement of multiple
metabolite compared to single (Pantel & Brakenhoﬀ, 2004). Broad lit-
erature range on extension and modiﬁcation of original sphere model is
too enormous to be discussed herein. Brieﬂy, the initial linear as-
sumption is replaced by non-linear equation proposed by Cristini and
colleagues relating the irregular shape of the spheres (Cristini,
Lowengrub, & Nie, 2003). They propose compact shape of highly vas-
cularized tumor compared to the fragmented ﬁngers under limited
nutrients.
Mathematical models can also be used as statistical tool to develop
new therapies including evaluation of response of those of existing in-
cluding chemotherapy and radiotherapy. The response of a spheroid
towards the treatment of a drug is expressed as (Mehta, Hsiao, Ingram,
Luker, & Takayama, 2012; Ward & King, 2003):
∂
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Where live cell density (cells/unit volume) = n, concentration of
nutrients = c, live cell velocity = v and concentration of drug = w are
dependent variables. r represents radius of spheroids. In Eq. (3), the rate
of change in numbers of cells per unit volume (n) is obtained from the
discrepancy between the rate of birth (κm(c)) and death(κd(c)); where
death is caused naturally or in response to drug at a rate ofKG(κm(c)f
(w)). Constant K represents the maximum achievable drug induced cell
death. The value of K can be used to predict patient-speciﬁc outcome of
speciﬁc therapeutics; beneﬁcial for the development of personalized
anti-cancer therapeutics.
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Eq. (4) depicts the nutrient diﬀusion by Fick's law. It permits to
model diﬀusion mediated transportation in nonhomogenous media.
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Eq. (5) represents the change in volume of spheroid measured by
subtracting the volume generated by birth (VLκm(c)n) from that of losing
by death ((VL−VD){κd(c)+KG(κm(c))f(w)}]n), where (VLn) state living
cell volume fraction, (1−VLn) state necrotic material volume fraction
and VL and VD are inverse phenomena (volume/cell) of a live and dead
cell.
Using these mathematical frameworks, the treatment response of a
tumor spheroid can be stimulated. When applied to a non-small cell
lung cancer, the stimulations qualitatively reproduce time dependent
morphogenesis of tumor in agreement with growth curves of patient
(Lecca & Morpurgo, 2012). Non-linear models of cancer growth are
more realistic representation of physiological cancer growth; help in
determining the administration schedule and therapy duration in clin-
ical practice.
The development of physiologically relevant in silico model is one of
the key approach in obtaining personalized therapy and is anticipated
to reveal predictive and prognostic biomarkers with low cost and in less
time.
3. Next generation in vitro modeling of cancer using biomaterials
Spheroids in cancer biology have already been envisioned as tool to
study the role of adhesion molecules (such as E-cadherin, Kallikrein-
related peptidase and integrin) or considered as organoid to study drug
sensitivity (Fennema, Rivron, Rouwkema, van Blitterswijk, & de Boer,
2013). With the advancement in sprouted innovative approaches im-
parting the controllability of tumor size (on a micrometer scale), re-
produces the desired native microenvironment of tumor. However, the
in vivo bi-directional interaction in terms of elasticity, rigidity between
cultured cells and surrounding niche is yet to achieve. Natural bioma-
terials such as collagen gel (Sabeh, Shimizu-Hirota, & Weiss, 2009) or
laminin-rich ECM (Kleinman & Martin, 2005) possess micro or nano
ﬁbril dimension of native ECM, therefore, used by cancer researchers
for past two decades. But these biomaterials often possess residual
growth factors or undeﬁned substances and suﬀer from batch to batch
variation. Hence, as advancement in cancer research, reproducible 3D
cell-culture system is desirable. Polyacrylamide gels are most exploited
to elaborate the putative role of matrix stiﬀness on tumor development
and progression (Pathak & Kumar, 2012). To unwind the underlying
mechanism of matrix induced mechanical cue, composition and
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architecture independent stiﬀ interpenetrating polymer network is
created using reconstituted basement membrane and alginate
(Chaudhuri et al., 2014); where stiﬀness is regulated by ionic cross-
linking of alginate without the change in polymer concentration. Cells
sense the enhanced stiﬀness through β4 integrin and PI3K pathway,
results in loss of apicobasal polarity and basement membrane invasion.
The ability to regulate the mechanical properties of biomaterials per-
mits us to investigate if the diﬀerent population of tumor cells in 3D
prefer hard or soft environment. The application of tissue engineering
concepts in tumor research focus on designing of scaﬀolds or hydrogels
mimicking the feature of ECM (Fennema et al., 2013).
Natural biomaterials obtained from the mammalian ECM, therefore,
are gaining attention namely hyaluronic acid and ﬁbrin, have good
control over quantity of ECM proteins and growth factors with low
immunogenicity (Chwalek, Bray, & Werner, 2014; Koch et al., 2014;
Yue et al., 2015). Synthetic biomaterials, such as polyethylene glycol
(PEG), copolymers developed of PEG with poly(L-lactide) (PLLA) and
poly(D,L-lactide-co-glycolide) (PLGA) are also favored due to their in-
teresting proteolytic degradability, cell adhesion site and matrix stiﬀ-
ness; able to support the growth of cancer cells and tumor angiogenesis,
controlling myriad parameters etc. (Fuller & Howell, 2014; Ma et al.,
2012). Synthetic biomaterials also oﬀer ease in chemical modiﬁcations,
selective regulation on biochemical and mechanical properties
(Chwalek et al., 2014; Ma et al., 2012). Recenet advancement in
bioengineering enable the grafting of motifs like arginine-glycine-as-
partic acid (RGD) in synthetic polymers to explore the role of tumor cell
integrin in angiogenic signaling (Gill et al., 2012). Commercially
available polysaccharide Gellan gum is printed as sacriﬁcial template
within ﬁbroblast encapsulating hydrogels for vasculature (Miller et al.,
2012). The carbohydrate ﬁbers dissolves with time using medium
perfusion; leaving behind the void space for subsequent seeding and
growth of endothelial cells — serves as potential 3D matrix in cancer
cell research. To obtain precise spatiotemporal arrangement of cells
within 3D microenvironment, microﬂuidics and photo-patterning
techniques are used.
Micro-ﬂuidic vascular cancer model obtained so far is grouped into
two categories; (i) micro-fabricated molds containing parallel micro-
ﬂuidic channels (Nguyen et al., 2013) and (ii) vascular structures
completely embedded in 3D matrix (Miller et al., 2012). Micro-fabri-
cated mold is obtained by embedding micro-channels within collagen
hydrogel, facilitating the real-time quantiﬁcation of tumor relevant
hydrodynamic stresses using microparticle image velocimetry
(Buchanan et al., 2014). The vascular structure is generated using
human-iPSC derived cells cultured in cardiac ECM along with cardiac
muscle and solid tumor into an integrated physiological system (Moya,
Tran, & George, 2013). Metastatic invasion is incorporated at the tumor
vascular interface, designed using microﬂuidics; compromised of two
independent channels seeded with tumor and endothelial cells and
connected by type I collagen hydrogel ECM (Zervantonakis et al.,
2012). The “tumor on chip” supports live imaging, manipulation of
micro-environmental factors and measurement of endothelial barrier.
The conceptual progresses emerge the hallmark of cancer research by
including reprogrammed energy metabolism, recruiting ostensibly
normal cells and immune cells in acquisition of in vivo tumor. The
Fig. 2. Proposed approach to an innovative, simple and ambitious 3D in vitro model perfomed by hydrogels, using 1 and/or 2 strategies. 1: (A) Biomaterial with tumor and healthy cells
encapsulated, (B) Tumor maturation, (C) Secondary tumor formation. 2: (D) Biomaterial with tumor or healthy cells encapsulated, grown into a bioreactor, (E) Rapid tumor maturation,
(F) Secondary tumor formation.
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insight is expected to aﬀect the development of new cancer therapy.
Bio-printing technology is being applied to generate methacrylate-
gellan gum (Me-GG) based 3D cell-matrix constructs with controlled
architectures for several tissue engineering applications (Billiet,
Gevaert, De Schryver, Cornelissen, & Dubruel, 2014; Hickman et al.,
2014; Silva-Correia et al., 2012; Yue et al., 2015). Combining the
principles of tissue engineering with microﬂuidics; “organ-on-chip” is
achieved, which mimics physiological environment and interactions
allowing the quantitative measurements of circulating tumor cells, ex-
travasation and micro-metastasis (Carvalho et al., 2015). Bioprinting
also allows fabricating micro-vessel models as microﬂuidic channels to
capture the native angiogenesis process within MCTSs more accurately,
as illustrated in Fig. 2. The choice of bio-inks for tumor modeling is
critical, taking into consideration its printability, biocompatibility,
cross-linking agents, viability of printed cells etc. and well discussed
elsewhere (Knowlton, Onal, Yu, Zhao, & Tasoglu, 2015; Zhang et al.,
2016). Me-GG solution mixed with chondrocyte cells is successfully bio-
printed into multiple layered network structures without losing cellular
viability (Schuurman et al., 2013). Me-GG also imparts thermal gela-
tion, which aids in retaining the shape of printed constructs
(Schuurman et al., 2013; Song, Park, & Gerecht, 2014). The viability of
hepato-carcinoma cells within this printed gels are directly related with
needle shape and printing pressure (Billiet et al., 2014). Usually two
types of cross-linking strategies are adopted in bio-inks, physical and
ionic crosslinking; both of which can be applied for Me-GG and referred
as iME-GG (ionic) or phMe-GG (photo-crosslinked) (Silva-Correia et al.,
2013). The approaches are likely to be useful in achieving the func-
tional bio-printed cancer tissue in near future.
4. Future directions
The present review revisits, reﬁnes and extends up to the conceptual
understanding of the available engineering approaches and in silico
models of in vitro cancer. The acquired models have stood the test of
time — further reﬁnement is deﬁnitely to be foreseen in future; con-
tributing towards the conceptual progress from past decades. Despite
the remarkable substantial journey from 2D to 3D, the limitations such
as sophisticated animal models well eliciting the large tumor hetero-
geneity like human cancer, advanced metastasis models including the
development of steps of metastatic cascade and incorporation of fully
functional immune system still exists.
To restore complete native microenvironment, in vitro systems are
necessary to deﬁne with precision. Many strategies are planned, but the
secret possibility resides in simplicity of ideas. The replacement of in
vivo animal models by 3D culture models in terms of successful re-
production of complete colossal complexity of cancer biology and me-
tastases — is not projected yet. But breaking down of pathological and
physiological complexity into amenable number of experimental in-
teractions in 3D is envisioned; serving as drug response platform, in-
vestigation of biomarkers, chemotherapeutic resistance and alternative
combinational approach to overcome the resistance approach is pos-
sible to mirror using 3D models.
The architecture theory of ‘form follows function’ appears be true in
tumor organoid culture; bridging the gap between cancer genetics and
patient trials, augment cell-line- and xenograft-mediated drug response
studies (van de Wetering et al., 2015). This initiative emphasizes MCTSs
encapsulation within suitable biomaterials, holds great potential. For
scaﬀold based approaches, the type of the materials used should be
carefully selected keeping in mind the nature of drugs to be screened
(Nugraha et al., 2011) or the purpose of the study. For instance,
horseradish peroxidase crosslinked silk ﬁbroin hydrogel system sup-
presses angiogenesis and tumor both in vitro and in vivo (Yan et al.,
2016); therefore, not applicable for tumor modeling study but suitable
for anti-cancer therapeutics. Self-assembled peptide hydrogels obtained
by entanglement of ﬁbrillary structure through supramolecular inter-
actions is also attractive for in situ gelation and micro- ﬂuidic chips
(Huang, Ding, Sun, & Nguyen, 2013). However, long-term stability of
such material is needed to be investigated.
The revolution of cancer genetics and proteomics is collection of
“big data”. Data generated using biomaterial library, patient care and
scientiﬁc research help to have closer look into multi-dimensional
cancer map; allow us to correlate gene expression with cellular path-
ways. The analysis of cellular pathways of cancer in detail is needed,
which not only gives more insight in the molecular processes of me-
tastasis but can be applied in improvement of existing models; un-
winding new targets of disease progression. Speciﬁc disease relevance
along with the processing eﬃcacy needs to be evaluated to promote the
“pay for performance” concept, while reduce the cost of health care. In
this regard, 3D metastasis models developed further turned into human
tumor platform as personalized medicine, for evaluating tumor pro-
gression of individual patients, using their own tumor cells. There is the
hope of using great personalized models in prospection of successful
clinical result (high-throughput screening).
5. Executive summary
The constraints of existing models are now well understood. Despite
advances in biomedical engineering and medicine, cancer still remains
a major health issue. Tumor spheroid is no doubt a versatile and po-
tential biomimicry tool in cancer research and therapeutic develop-
ment; but not enough to model the complex biology of cancer, in par-
ticular the metastasis cascade. Hence, involvement of microfabrication
process and computer-based algorithms are needed to capture the as-
pects of metastasis more precisely than yet realized. Engineering hu-
manized organ model in laboratory animal is an alternative approach to
in vitro culture system, but co-implantation of biomaterials and
spheroid culture as key component of the system; recognizing the in-
escapable role of biomaterials in 3D cancer research. Furthur, given the
acknowledgement that tumor microenvironment is the predominant
shelter of surviving tumor cell population following chemotherapy;
recapitulate it using biomaterials may unwind the underlying insight of
ECM mediated drug resistance. We anticipate biomaterial based ad-
vanced cancer spheroid are expected to translate better personalized
patient-speciﬁc therapeutic interventions.
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